Private asset manager Bridgepoint has exited its majority investment in sports nutrition company Vitamin Well with a sale to international private equity firm Cinven, which is now the company’s largest shareholder and lead investor.
Bridgepoint will retain a significant minority shareholding in Vitamin Well.
Established in 2008 and headquartered in Stockholm, Vitamin Well employs around 500 and manages the brands Vitamin Well (vitamin and mineral-enriched drinks), NOCCO (performance energy drinks) and Barebells (protein bars and shakes), which are sold internationally across more than 40 markets.
Bridgepoint first invested in Vitamin Well in 2016 by a fund managed by Bridgepoint Development Capital, Bridgepoint’s lower middle-market strategy. It has been co-owned with Bridgepoint Europe, Bridgepoint’s middle-market strategy, since 2021 following additional investment. Both funds will retain a significant minority stake in the business going forward.
Bridgepoint supported the company’s expansion into markets including the DACH region, the UK, Spain and the US.
The transaction is expected to complete in H2 2024.
Bridgepoint was advised by Jefferies, Vinge, McKinsey and PwC.
